Pasithea director granted 152,783 stock options
Pasithea Therapeutics Corp. director Simon Dumesnil received a grant of stock options covering 152,783 shares of common stock.
Rhea-AI Filing Summary
Pasithea Therapeutics Corp. director Simon Dumesnil received a grant of stock options covering 152,783 shares of common stock. The options have an exercise price of $0.841 per share and were awarded as compensation under the company’s 2023 Stock Incentive Plan.
The options vest in full on the one-year anniversary of the grant date if he remains a director, and will fully vest earlier upon a defined Change in Control. Following this grant, Dumesnil holds 152,783 derivative securities representing rights to acquire common shares, with the options scheduled to expire on April 30, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 152,783 shares
Grant/Award
1 txn
Insider
Dumesnil Simon
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 152,783 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 152,783 contracts (Direct)
Footnotes (1)
- F1. The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan).
Key Figures
Options granted: 152,783 options
Exercise price: $0.841 per share
Underlying shares: 152,783 shares
+2 more
5 metrics
Options granted
152,783 options
Stock Option (right to buy) grant on May 1, 2026
Exercise price
$0.841 per share
Conversion or exercise price for the stock options
Underlying shares
152,783 shares
Common stock underlying the stock options
Post-grant derivative holdings
152,783 options
Total derivative securities following the transaction
Option expiration date
April 30, 2036
Expiration date of the stock options
Key Terms
2023 Stock Incentive Plan, Change in Control, stock option, vesting
4 terms
2023 Stock Incentive Plan financial
"The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended"
Change in Control financial
"the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan)"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
stock option financial
"The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting financial
"underlying the Option will vest in full upon the one-year anniversary of the date of grant"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Simon Dumesnil acquire in this Pasithea Therapeutics (KTTA) Form 4?
Simon Dumesnil received a grant of stock options for 152,783 Pasithea Therapeutics shares. These options were awarded as compensation, not bought on the open market, giving him the right to purchase common stock at a fixed exercise price if vesting conditions are met.
What is the exercise price of the Pasithea Therapeutics (KTTA) options granted to Dumesnil?
The options granted to Simon Dumesnil carry an exercise price of $0.841 per share. This means he can buy Pasithea Therapeutics common stock at $0.841 if the options vest and are exercised, regardless of the market price at that time.
When do Simon Dumesnil’s Pasithea Therapeutics (KTTA) options vest?
The options vest in full on the one-year anniversary of the grant date, assuming Dumesnil remains a director. The footnote also states that all underlying shares vest immediately if a Change in Control, as defined in the 2023 Stock Incentive Plan, occurs earlier.
How many Pasithea Therapeutics (KTTA) options does Dumesnil hold after this transaction?
After this grant, Simon Dumesnil holds 152,783 stock options representing rights to acquire Pasithea Therapeutics common shares. This entire position comes from the new award reported in the Form 4, with no additional derivative positions listed in the filing’s summaries.
Are the Pasithea Therapeutics (KTTA) options granted to Dumesnil an open-market purchase?
No, these options are a compensation grant under Pasithea Therapeutics’ 2023 Stock Incentive Plan. The Form 4 shows transaction code A for an award, with a transaction price of $0.000, indicating no cash was paid to acquire the options themselves.
AI-generated analysis. How Rhea-AI works. Not financial advice.
